Economic analysis 20 years after the introduction of Universal HBV immunisation in Bulgaria

Biotechnology and Biotechnological Equipment

Volumn 26, Issue 1, 2012, Pages 2811-2816

  Savova, Alexandra ^a   Petrova, Guenka ^a   Gotseva, Aneliya ^b   Kurcatova, Anna ^c   Koguharova, Mira ^c  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b University Specialized Hospital for Intensive Care   (Bulgaria)

^c NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

Author keywords

Cost of pharmacotherapy; Health economics; Hepatitis B; Vaccination

Indexed keywords

BULGARIA; CHRONIC HEPATITIS; COST ANALYSIS; ECONOMIC RESULTS; HEALTH BENEFITS; HEALTH ECONOMICS; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; HOSPITAL DISCHARGE; VACCINATION;

COST ACCOUNTING; COSTS; ECONOMIC ANALYSIS; HOSPITALS; IMMUNIZATION; VIRUSES;

COST BENEFIT ANALYSIS;

HEPATITIS B VIRUS;

EID: 84857545757     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.5504/bbeq.2011.0141     Document Type: Article

References (26)

1. Andre F.E., Booy R., Bock H.L., Clemens J., Datta S.K., John T.J., Lee B.W., Lolekha S., Peltola H., Ruff T.A., Santosham M., Schmitt H.J. (2008) Bulletin of the World Health Organization, 86, 140-146.
2. Beutels P. (2001) Health Econ., 10(8), 751-774.
3. Beutels P., Edmunds W.J., Antoñanzas F., de Wit G.A., Evans D., Feilden R., Fendrick A.M., Ginsberg G.M., Glick H.A., Mast E., Péchevis M., van Doorslaer E.K.A., van Hout B.A. (2002) PharmacoEconomics, 20(1), 1-7.
4. Bloom B.S., Hillman A.L., Fendrick A.M., Schwartz J.S. (1993) Ann. Intern. Med., 118, 298-306.
5. Drummond M., Chevat C., Lothgren M. (2007) Vaccine, 25, 5945-5957.
6. Ehreth J.(2003) Vaccine, 21, 4112.
7. Goldstein S.T., Alter M.J., Williams I.T., Moyer L.A., Judson F.N., Mottram K., Fleenor M., Ryder P.L., Margolis H.S.(2002) J. Infect. Dis., 185, 713-719.
8. Jacobs R.J., Meyerhoff A.S. (2004) J. Adolescent Health, 34(5), 420-423.
9. Kao J-H., Chen D-S. (2002) The Lancet Infectious Diseases, 2(7), 395-403.
10. Krahn M., Detsky A.S. (1993) Med. Decis. Making, 13, 4-20.
11. Lahaye D., Baleux C., Strauss P., Van Ganse W. (1987) The Lancet, 330(8556), 441-443.
12. Lavanchy D. (2004) J. Viral Hepat., 11(2), 97-107.
13. Levine R. (2003) In: The Vaccine Book (Bloom B.R., P.H. Lambert, Eds.), Academic Press, San Diego, 23-35.
14. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., Zhang Y., Liu J., Gong X., Chen Y., Wang F., Zheng H., Wang F., Guo J., Jia Z., Ma J., Wang H., Luo H., Li L., Jin S., Hadler S.C., Wang Y. (2009) J. Infect. Dis., 200, 39-47.
15. Mangtani P., Hall A.J., Normand C.E. (1995) Epidemiol. Community Health, 49, 238-244.
16. Ministry of Health. Positive Dug List Committee and Pricing Committee Registries, www.mg.government.bg (In Bulgarian)
17. Mitkov Tz., Tzenova A., Danchev N., Petrova G. (2004) Arch. Farm., 54, 823-841.
18. NHIF (2010) National Framework Contracts 1989 - 2010, www.nhif.bg (In Bulgarian)
19. Nichol K.L. (2001) Arch. Intern. Med., 161, 749-759.
20. Plotkin S.L., Plotkin S.A. (2004) In: Vaccines, 4th Ed. (S.A. Plotkin, W.A. Orenstein, Eds.), WB Saunders, Philadelphia, 1-15.
21. Rascati K.L. (2009) Essential of Pharmacoeconomics, Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, London, pp. 89-109.
22. U.S. Centers for Disease Control and Prevention (2003) MMWR (Morbidity and Mortality Weekly report), 52(36), 868-870.
23. Van Damme P., Tormans G., Beutels P., Van Doorslaer E. (1992) Vaccine, 13(1), S54-S57.
24. Viral Hepatitis Prevention Board (2011) Meetings and Publications, Presentations, Treatment and laboratory monitoring of chronic hepatitis patients in Bulgaria, March 2011, www.vhph.org
25. WHO (1992) Expanded Programme on Immunization, Global Advisory Group-part I. Wkly Epidemiol. Rec., 67(3), 11-15.
26. Zuckerman J., van Hattum J., Cafferkey M., Gjørup I., Hoel T., Rummukainen M-L., Weiland O. (2007) The Lancet Infectious Diseases, 7(6), 410-419.